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Glucocorticoid-induced leucine zipper (GILZ) is a dexamethasone-inducible gene that
mediates glucocorticoid (GC) actions in a variety of cell types, including many cells
of immune system. In particular, GILZ can control T cell activities, such as activation
and differentiation, mainly through its ability to homo- and hetero-dimerize with partner
proteins, such as NF-κB, Ras, and C/EBP. These protein–protein interactions control the
regulation of pro-inflammatory target genes. A number of in vitro and in vivo studies using
mouse models of inflammatory diseases demonstrate an anti-inflammatory role for GILZ.
Here, authors summarize the studies that make GILZ eligible as an anti-inflammatory
protein through which GCs can act. These findings permit the future development of
pharmacological tools that mimic the therapeutic effects of GCs while avoiding the
detrimental ones.
Keywords: glucocorticoids, GILZ, inflammation, immune cells, transcription factor
INTRODUCTION
Glucocorticoid-induced leucine zipper (GILZ) is a dexamethasone-inducible gene belonging to
the TSC-22 family of proteins, which are characterized by the presence of TSC box and leucine
zipper domains (1). GILZ expression is rapidly and ubiquitously induced by glucocorticoids (GCs)
in various types of cells, including lymphoid cells, in which it regulates activation and apoptosis.
An emerging body of literature has established GILZ as an important mediator of GC anti-
inflammatory effects in cell lineages and in inflammatory mouse models, by inhibiting expression
of pro-inflammatory genes (2–4). This effect resides in the ability of GILZ to homo- and hetero-
dimerize with known transcription factors, thereby influencing gene transcription. Some of these
partner proteins are NF-κB, Raf-1, TORC2, AP-1, Ras, and C/EBPs; all of these transcription factors
are pivotal players in pro-inflammatory signaling pathways. Some of them, such as NF-κB and Raf-
1/Ras, are even involved in oncogenesis signaling pathways. TORC2 is specifically bound by GILZ
in BCR–ABL cells, leading to apoptosis (5). GILZ has also been found to be involved in allergy,
being downregulated in DCs of respiratory allergic patients or in the airways of allergen-challenged
asthmatic subjects and upregulated after GC treatment (6, 7). Thus, GILZ plays a pivotal role into
the inflammatory processes of various sources.
Glucocorticoids are the most used anti-inflammatory drugs by virtue of their powerful effects on
the cells of the immune system. However, these drugs also exhibit detrimental side effects, which
can limit their usefulness. It is commonly assumed that transactivation accounts for the onset of side
effects as a consequence of the metabolic activity of GCs, and transrepression for the therapeutic
effects via inhibition of pro-inflammatory proteins. Nonetheless, GILZ is one of the earliest and
mostGC inducible genes by transactivation, aswell as other geneswith anti-inflammatory properties
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(e.g., Iκ-B). Therefore, the transactivation process is responsible
also for some anti-inflammatory effects of GCs, through the use
of GILZ as a mediator (4, 8, 9).
Glucocorticoid-induced leucine zipper is currently considered
an importantmolecular player in themultiplemechanisms of GC-
influenced gene regulation of inflammation and a new focus for
anti-inflammatory strategies.
GILZ INTERACTION WITH
TRANSCRIPTION FACTORS
Inhibition of the transcription factor NF-κB represents one of
the mechanisms by which GCs repress gene activation without
binding DNA, through an indirect pathway, in a process called
transrepression (10, 11). GILZ is postulated to be a mediator
of GC-induced transrepression because it can bind NF-κB and
inhibit nuclear translocation of the transcription factor, in T
cells and TCR-triggered thymocytes (12–14). As a consequence
of this interaction, expression of some immune and inflam-
matory response genes is repressed. In T cells, overexpression
of GILZ counteracts the NF-κB-induced up-regulation of the
Fas/FasL system, thus preventing activation-induced apoptosis
(1). In thymocytes, the same mechanism seems to be responsi-
ble for the inhibition of cell death, controlled by some NF-κB-
regulated genes (12, 15). Very recently, in B cells, lack of GILZ
has been found to cause increased NF-κB transcriptional activity
with consequent contribution to the development of non-lethal
B lymphocytosis (16). In bone marrow mesenchymal stem cells,
GILZ inhibits COX-2 expression through inhibition of NF-κB.
Furthermore, GILZ knockdown reduces GC inhibitory effect on
cytokine-induced COX-2 expression, further demonstrating that
GILZ can be a mediator of GC effects (17).
The interaction between GILZ and NF-κB has many other
consequences. A particular, and still unexplained, interaction
with NF-κB comes from studies in endothelial cells. IL-10 was
found to upregulate GILZ in human umbilical vein endothelial
cells (HUVEC), thus contributing to the failure to endothelium-
dependent costimulation of CD4 T cells (18). In another study
with the same cell type, overexpression of GILZ decreased TNF-
induced transmigration of leukocytes by inhibition of NF-κB
binding to DNA (19). These results would suggest that GILZ
is involved in leukocyte rolling and adhesion. Interestingly, nei-
ther physical interaction between GILZ and the p65 NF-κB
subunit nor inhibition of NF-κB translocation to the nucleus
was observed. Thus, the exact mechanism through which GILZ
inhibits NF-κB is still unclear. Similarly, another study demon-
strated that endogenous expression of GILZ in HUVEC prevents
vascular inflammation via inhibition of NF-κB nuclear transloca-
tion (20). Thus, NF-κB represents a key target for GILZ-mediated
GC anti-inflammatory activity, and, by consequence, GILZ rep-
resents a potential target for treatment of inflammation in the
endothelium.
Glucocorticoid-induced leucine zipper was also found to
homo- and hetero-dimerize withAP-1 pathway components, such
as c-Jun and c-Fos. GILZ can bind c-Jun and c-Fos through its N-
terminal region, thereby inhibiting AP-1-driven activation. Such
an interaction contributes to the regulation of AP-1 activity by
GCs through a mechanism different from GR direct binding to
transcription factors (21).
Although GILZ has been found to antagonize the activity of
transcription factors, such as NF-κB and AP-1, it can also act
as a chaperone protein. GILZ expression is induced by aldos-
terone in cortical collecting tubules in the kidney. Once induced,
GILZ contributes to the stimulation of epithelial sodium channel
(ENaC)-mediated Na+ transport via mineralocorticoids through
the inhibition of the ERK cascade (22, 23). Through a second
GILZ-dependent mechanism, ion transport can be controlled
through physical interaction between GILZ and serum, and
glucocorticoid-induced kinase 1 (SGK1). GILZ stabilizes SGK1 by
recruiting it to the ER. This event inhibits SGK1 ubiquitination
and, as a result, ENaC is activated (24). Therefore, GILZ represents
a key regulator of transepithelial ion transport in the kidneys.
Pharmacological treatment with GCs is known to promote
osteoporosis; however, osteoporosis can be induced by chronic
inflammation as well (25). GILZ, despite being a GC-induced
gene, is involved in the regulation of osteogenesis. In mesenchy-
mal stem cells, GILZ acts as a transcriptional repressor by inhibit-
ing C/EBP-δ-induced PPAR-γ2 expression, a key regulator of
adipogenesis. GILZ binds specifically to tandem C/EBP sites in
the promoter, forming complexes with C/EBP-δ and other still
unknown transcription factors, thus inhibiting expression of the
target genes (26, 27). Therefore, GILZ can drive the differentia-
tion of mesenchymal stem cells toward the osteogenic pathway.
These findings suggest that GILZ expression is important for
osteoblast differentiation, whereas lack of GILZ can trigger the
maturation of adipocytes. Overall, GILZ expression tips the bal-
ance of mesenchymal stem cell commitment in the bone marrow,
playing an opposing role to GCs, which induce the differentia-
tion toward adipocytes (28). Most likely, GILZ can temper the
damage caused to bones by chronic inflammation because of its
anti-inflammatory properties.
GILZ AND T LYMPHOCYTES
Control of lymphocyte function during an immune response by
means of GCs implies regulation of activation and apoptosis of T
cells. GILZ was found to modulate T lymphocyte response in the
murine cell line 3DO; overexpression ofGILZ inhibited anti-CD3-
induced apoptosis through the regulation of the Fas/FasL system
(1). Thereafter, our laboratory reported that GILZ inhibits TCR-
induced IL-2 and IL-2 receptor expression, which can explain the
aforementioned effect on the inhibition of Fas/FasL expression
and consequent T cell survival (12). These results indicate GILZ
counters TCR-induced T cell activation, thus contributing to T
cell anergy (Figure 1). Since then, additional studies have been
published, supporting a role ofGILZ as amediator ofGC action on
T lymphocytes, through its function in regulating the homeostasis
of these cells (3). One mechanism by which GILZ regulates T
lymphocyte is through IL-2, the main survival interleukin in
activated T lymphocytes. IL-2 is downregulated by GILZ, and
it also inhibits GILZ expression through the repression of the
transcription factor FoxO3, which directly acts onGILZ promoter
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FIGURE 1 | Glucocorticoids control T cell activation through up-regulation of GILZ. GILZ inhibits TCR-induced IL-2 and IL-2 receptor expression, which in
turn inhibits Fas/FasL expression, promoting T cell survival and anergy.
(12, 29). Therefore, FoxO3 seems to be the mediator of GC action
and IL-2 antagonism for GILZ regulation in T lymphocytes. In
turn, GILZ negatively regulates FoxO factors, such as FoxO1,
FoxO3, and FoxO4 (30).
Like GCs, GILZ can modulate a switch from Th1 to Th2
immune phenotypes, as demonstrated by the up-regulation and
down-regulation of Th2 and Th1 cytokines, respectively. This
conclusion was demonstrated in CD4+ cells of GILZ transgenic
mice (TG), where an increase of IL-4 and a decrease of IFN-γ
were observed. This shift in cytokine expression causes GILZ TG
mice to be less susceptible to the induction of colitis. Much like
what has been observed for the other transcription factors, GILZ
can regulate the transcription of factors that control Th1- and
Th2-specific cytokine expression. GILZ up-regulates GATA 3 and
STAT6 to modulate the Th2 phenotype, and downregulates T-bet
to modulate the Th1 phenotype (9).
GILZ plays another important role by contributing to the TGF-
β-mediated generation of peripheral Treg (pTreg). GCs synergize
with TGF-β signaling to increase Treg formation in upregulating
Foxp3, the master regulator transcription factor of Tregs (31).
GILZ-knock-out (KO) mice show a reduction of pTreg cells due
to a diminished TGF-β signaling. As a consequence, an increased
susceptibility toDNBS-induced Th1-type colitis is associated with
GILZ absence. Thus, GILZ represents the means by which stress
hormones encounter TGF-β signaling in the control of pTreg
production (32).
Most recently, GILZ was found to regulate Th17 cells. GILZ
controls the secretion of IL-17A by CD4 T cells by regulating the
expression of cytokines favoring the Th17 phenotype, such as IL-
1α, IL-23, and IL-6. In the mouse imiquimod model of psoriasis,
in which Th17 lymphocytes play a pathogenic role, GILZ-KO
mice developed excessive inflammation and exhibited enhanced
pro-inflammatory cytokine expression. These results suggest that
Th17 cells are another T cell subtype controlled by GILZ (33).
Glucocorticoid-induced leucine zipper is also pivotal in con-
trolling T lymphocyte functions prior to their maturation in
the thymus. Constitutive GILZ overexpression in GILZ-TG mice
causes an increase in apoptosis, which is associated with an aug-
mented activation of the caspase-8/caspase-3 pathway. As a conse-
quence, adultGILZ-TGmice show a reduced number of CD4 and
CD8 double positive thymocytes (34). In addition, GILZ prevents
apoptosis induced by stimulation of TCR in thymocytes through
the inhibition of NF-κB (15). Because GCs induce apoptosis in
thymocytes and rapidly upregulate GILZ, the latter represents the
mediator of GC action in the thymus.
GILZ FUNCTION IN MOUSE MODELS OF
INFLAMMATION
Because GILZ is involved in the inflammatory process, it has
been studied in many of the mouse models for inflamma-
tory diseases. Inflammatory bowel diseases (IBDs) are autoim-
mune/inflammatory diseases of the gastrointestinal tract that
can be easily reproduced in mice. IBDs are usually treated with
GCs; thus, given the relationship between GILZ and GCs, the
role of GILZ has been studied in rodent models of IBDs. In
TG mice overexpressing GILZ in CD4+ cells, the severity of
colonic inflammation is diminished compared to the controlmice.
This result suggests that GILZ inhibits Th1 activation in favor
of the Th2 commitment of CD4+ cells exerted. Furthermore,
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treatment of IL-10-KO mice with a recombinant TAT–GILZ
protein reduces the severity of spontaneously developed colitis
(8). The Th2 phenotype of GILZ-TG mice was shown previ-
ously in another Th2-driven disease and model of inflammation:
bleomycin-induced lung injury. GILZ-TG mice exhibit a more
severe bleomycin-induced lung injury, but they are protected
under a Th1-dependent delayed-type hypersensitivity response
(9). From these data, onemight hypothesize that the effect of GILZ
on Th2-driven differentiation overlaps with the action of GC.
Overexpression of GILZ in the TG mice has proven to be a
helpful tool in the study of GILZ in another model of inflamma-
tion, i.e., the post-traumatic disease that develops after spinal cord
injury (SCI). GILZ prevents the development of SCI mainly by
inhibiting T cell activation and the release of pro-inflammatory
cytokines, such as TNF-α and IL-1β (35). Similar effects on
activated T cells were found in a mouse model of experimental
autoimmune encephalomyelitis, in which a GILZ peptide (GILZ-
P) interacting with NF-κB was administered on the day of disease
onset. Treated mice were protected against the disease, demon-
strating the powerful control GILZ can exert on T cell activity
(36). Using the same inflammatory model, another study demon-
strated that the induction of GILZ in dendritic cells mirrors the
immunomodulation by GC in the control of autoaggressive T cell
responses (37).
Anti-inflammatory actions of GILZ are evident even in mouse
models of acute inflammation, such as endotoxemia.GILZ expres-
sion led to the resistance of SPRET/Ei mice to LPS-induced endo-
toxemia through an altered cytokine production. Furthermore,
mice that received in vivo administration of a pES34–TAT–GILZ
expression vector exhibited increased resistance to lethal effects
of LPS (38). In a second example, GILZ was studied in the
rodent model of LPS-induced pleurisy. Administration of recom-
binant TAT–GILZ protein accelerated the resolution phase of
acute inflammation, reducing the magnitude of PMN infiltra-
tion by inducing apoptosis (39). Lastly, GILZ modulates acute
inflammation in other cells of the innate system, themacrophages.
In a mouse model for LPS tolerance, GILZ was upregulated
in alveolar macrophages, whereas in endotoxin-tolerized GILZ-
KO macrophages, cytokine induction and MAPK activation were
rescued (40).
Glucocorticoid-induced leucine zipper plays a role in arthritis
as well. In the CIA model of arthritis, GILZ expression mimicked
the therapeutic effect of GCs, and deletion of GILZ increased the
severity of the disease together with the expression of TNF and
IL-1. Importantly, GILZ was found in the sinovium of patients
with active RA, suggesting GILZ is crucial for the regulation of
the local inflammatory response functioning as an endogenous
inhibitor of chronic inflammation (41). Overall, these examples
of GILZ involvement in inflammatory diseases clearly illustrate
that GILZ acts as a mediator for the GC therapeutic effect,
both in T lymphocytes and other cells of the innate immune
system.
BEYOND INFLAMMATION
The ability of GILZ to hetero-dimerize even with “non-LZ” pro-
teins extends its functions beyond inflammation to a number
FIGURE 2 | Glucocorticoid-induced leucine zipper inhibits Akt/Pkb and
ERK 1/2 pathways by binding to Ras and Raf, thus blocking cell
proliferation and transformation.
of additional pathways. GILZ can form heterodimers with Ras
and Raf from the MAP-kinase/ERK-kinase pathway, as well as
ternary complex with both binding partners, thereby control-
ling growth of the cell (42). Signaling through the Ras family
of small GTPases is pivotal in the transmission of mitogenic
stimuli to the cell cycle machinery. The fact that GILZ binds
predominantly to activated Ras, but not to Raf, suggests a fine
tuning of the regulation of this pathway. Interestingly, GILZ
binds to Raf when Ras in not activated. Thus, in the case of
activated Ras, both Akt/Pkb serine (threonine kinase) and ERK
pathways are inhibited by GILZ. When Ras is not activated, GILZ
can influence only the ERK pathway via interaction with Raf
(Figure 2).
CONCLUSION
In recent years, GILZ has emerged as a pivotal mediator of GC
action in the inflammatory process, as demonstrated by many
in vitro and in vivo studies. This GILZ function opens the pos-
sibility to develop new or repurposed pharmaceutical tools for the
treatment of inflammation-based diseases. These new therapies
could achieve obtaining the same effect as GC treatment, but
circumvent the undesirable side effects caused by GCs.
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